Human Type 3 3α-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
Human aldo-keto reductases (AKRs) of the AKR1C subfamily function in vitro as 3-keto-, 17-keto-, and 20-ketosteroid reductases or as 3α-, 17β-, and 20α-hydroxysteroid oxidases. These AKRs can convert potent sex hormones (androgens, estrogens, and progestins) into their cognate inactive metabolites or vice versa. By controlling local ligand concentration AKRs may regulate steroid hormone action at the prereceptor level. AKR1C2 is expressed in prostate, and in vitro it will catalyze the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of 3α-androstanediol (3α-diol) to 5α-dihydrotestosterone (5α-DHT). This reaction is potently inhibited by reduced NAD phosphate (NADPH), indicating that the NAD+: NADPH ratio in cells will determine whether AKR1C2 makes 5α-DHT. In transient COS-1-AKR1C2 and in stable PC-3-AKR1C2 transfectants, 5α-DHT was reduced by AKR1C2. However, the transfected AKR1C2 oxidase activity was insufficient to surmount the endogenous 17β-hydroxysteroid dehydrogenase (17β-HSD) activity, which eliminated 3α-diol as androsterone. PC-3 cells expressed retinol dehydrogenase/3α-HSD and 11-cis-retinol dehydrogenase, but these endogenous enzymes did not oxidize 3α-diol to 5α-DHT. In stable LNCaP-AKR1C2 transfectants, AKR1C2 did not alter androgen metabolism due to a high rate of glucuronidation. In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate. Thus, in prostate cells AKR1C2 acts as a 3-ketosteroid reductase to eliminate 5α-DHT and prevents activation of the androgen receptor. AKR1C2 does not act as an oxidase due to either potent product inhibition by NADPH or because it cannot surmount the oxidative 17β-HSD present. Neither AKR1C2, retinol dehydrogenase/3α-HSD nor 11-cis-retinol dehydrogenase is a source of 5α-DHT in PC-3 cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These enzymes preferably act as reductases in vivo since they have Kd values for NADPH in the nanomolar range, there is a high NADPH/NADP+ ratio within cells and NADPH inhibits the NAD+ dependent oxidation reactions at low μM concentrations”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“In peripheral tissues, AKR1C enzymes act as 3-keto and 17-ketosteroid reductases to catalyze either the formation of the most potent androgen 5α-dihydrotestosterone (5α-DHT) or its inactivation to yield the inactive androgens 5α-androstane-3α,17β-diol (3α-Diol) or 5α-androstane-3β,17β-diol (3β-Diol)”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“COS-1, PC-3 and LNCaP cells transfected with AKR1C2 were able to recapitulate this reaction”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C2 has the highest catalytic efficiency as a 3-ketosteroid reductase and catalyzes reduction of 5α-DHT to 3α-Diol”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C3 catalyzes the reduction of Δ4-androstene-3,17-dione to form the potent androgen testosterone (Kd = 10−9 M for AR) and the reduction of 5α-androstane-3,17-dione to yield the most potent androgen 5α-DHT (Kd =10−10 M for the AR).”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Self-citationThe induction of prostatic hypertrophy in the dog with androstanediol.
Walsh, P. C., & Wilson, J. D. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108353 · Cited by 418
A new nomenclature for the aldo-keto reductase superfamily
Jez, J. M., Flynn, T. G., & Penning, T. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)84253-0 · Cited by 354
Self-citationThe clinical development of a 5α-reductase inhibitor, finasteride
Stoner, E. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90487-6 · Cited by 224
Biswas, M. G., & Russell, D. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15959 · Cited by 224
Hormones and Prostate Cancer: What's Next?
Hsing, A. W. (2001) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a000795 · Cited by 216
Lin, H.-K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., & Penning, T. M. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.13.0026 · Cited by 194
Self-citationThe role of androgens and the androgen receptor in prostate cancer.
Debes, J. D., & Tindall, D. J. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00413-5 · Cited by 191
Davies, P., & Eaton, C. L. (1991) · Journal of Endocrinology · doi:10.1677/joe.0.1310005 · Cited by 158
BRUCHOVSKY, N. (1971) · Endocrinology · doi:10.1210/endo-89-5-1212 · Cited by 153
Roehrborn, C. G., Bartsch, G. H., Kirby, R. S., Andriole, G. L., Boyle, P., de la Rosette, J. J. M. C. H., Perrin, P., Ramsey, E. W., Nordling, J., Freire, G. D. C., et al. (2001) · Urology · doi:10.1016/s0090-4295(01)01402-9 · Cited by 146
Burczynski, M. E., Harvey, R. G., & Penning, T. M. (1998) · Biochemistry · doi:10.1021/bi972725u · Cited by 133
Self-citationProstate formation in a marsupial is mediated by the testicular androgen 5α-androstane-3α,17β-diol
Shaw, G., Renfree, M. B., Leihy, M. W., Shackleton, C. H. L., Roitman, E., & Wilson, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220412297 · Cited by 101
Purification and Properties of Multiple Forms of Dihydrodiol Dehydrogenase from Human Liver1
Hara, A., Taniguchi, H., Nakayama, T., & Sawada, H. (1990) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123189 · Cited by 87
Virilization of the Wolffian Duct in the Rat Fetus by Various Androgens
MICHAEL SCHULTZ, F., & WILSON, J. D. (1974) · Endocrinology · doi:10.1210/endo-94-4-979 · Cited by 86
Function of human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase in androgen metabolism
He, X., Merz, G., Yang, Y., Pullakart, R., Mehta, P. D., Schulz, H., & Yang, S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00014-7 · Cited by 76
Human Types 1 and 3 3α-Hydroxysteroid Dehydrogenases: Differential Lability and Tissue Distribution1
Dufort, I., Labrie, F., & Luu-The, V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7216 · Cited by 73
Enzymes of Androgen Formation and Degradation in the Human Prostate
BARTSCH, W., Klein, H., Schiemann, U., Bauer, H. W., & Voigt, K. D. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb34282.x · Cited by 66
Further characterization of human microsomal 3α-hydroxysteroid dehydrogenase
Chetyrkin, S. V., Hu, J., Gough, W. H., Dumaual, N., & Kedishvili, N. Y. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2203 · Cited by 60
Barbier, O., Lapointe, H., El Alfy, M., Hum, D. W., & Bélanger, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7019 · Cited by 56
Castagnetta, L. A. M., Carruba, G., Traina, A., Granata, O. M., Markus, M., Pavone-Macaluso, M., Blomquist, C. H., & Adamski, J. (1997) · Endocrinology · doi:10.1210/endo.138.11.5497 · Cited by 45
Hardy, D. O., Ge, R.-S., Catterall, J. F., Hou, Y.-T., Penning, T. M., & Hardy, M. P. (2000) · Endocrinology · doi:10.1210/endo.141.5.7445 · Cited by 34
Self-citationHorst, H.-J., Dennis, M., Kaufmann, J., & Voigt, K. D. (1975) · Acta Endocrinologica · doi:10.1530/acta.0.0790394 · Cited by 25
Guillemette, C., Hum, D. W., & ́langer, A. B. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00183-2 · Cited by 23
Huang, X., & Luu-The, V. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00200-x · Cited by 20
Tsuruda, L., Hou, Y., & Penning, T. M. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0100035 · Cited by 19
Self-citationSpan, P. N., Sweep, F. C. G. J., Benraad, T. J., & SMALS, A. G. H. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00036-2 · Cited by 17
Modulation of the androgenic response by recombinant human 11-cis retinol dehydrogenase
Huang, X., & Luu-The, V. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00038-3 · Cited by 14
Studies on the effect of 5α-androstane-3α, 17α-diol in the canine prostate in vivo
McDermott, I. R., Robinson, C. H., & Deklerk, D. P. (1978) · Steroids · doi:10.1016/0039-128x(78)90033-8 · Cited by 11
Research works printed but not linked: 3
- Griffiths, 1999, Aspects of the cell biology of prostate cancer, 51
- Barbier, 2000, Cellular localization of uridine diphosphoglucronsyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistichemistry., J Clin Endocrinol Metab, 85, 4819
- Peehl, 1992, Culture of human prostate epithelial cells, 159
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
“Previous studies found that expression of AKR1C2 was decreased in primary prostate cancer relative to normal prostate, and this was proposed as a mechanism for increasing intracellular dihydrotestosterone in primary prostate cancer (53, 54).”
BackgroundSelf-citationThe aldo-keto reductases (AKRs): Overview
Penning, T. M. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.024 · Cited by 543
Self-citationGonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
“[PubMed: 7958169] Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism.”
InfluentialAldo-Keto Reductases and Bioactivation/Detoxication
Jin, Y., & Penning, T. M. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105337 · Cited by 383
Self-citation
Metadata
- Authors
- Rižner, T. L., Lin, H. K., Peehl, D. M., Steckelbroeck, S., Bauman, D. R., & Penning, T. M.
- Affiliations
- Department of Pharmacology, University of Pennsylvania School of Medicine (T.L.R., T.M.P., S.S., D.M.B.), Philadelphia, Pennsylvania 19104-6084
- University of Oklahoma Health Sciences Center (US)
- University of Pennsylvania (US)
- Stanford Medicine (US)
- Corresponding author
- Penning, Trevor M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-07-01
- Volume
- 144
- Issue
- 7
- Pages
- 2922-2932
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2125072209
- Cited by
- 132
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 5 · 2016: 10 · 2014: 10 · 2013: 10 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 97044)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54925, DK-47015, R01DK054925, R01DK047015)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- 3α-hydroxysteroid dehydrogenase, AKR1C2, aldo-keto reductase, androgen metabolism, dihydrotestosterone, 3α-androstanediol, 17β-hydroxysteroid dehydrogenase, androgen receptor activation, prostate cancer, PC-3 cells, LNCaP cells, glucuronidation
- MeSH terms
- Adenocarcinoma, Animals, Bone Neoplasms, Epithelial Cells, Humans, Hydroxysteroid Dehydrogenases, Isoenzymes, Male, Prostate, Prostatic Neoplasms, Dihydrotestosterone, Testosterone, Tumor Cells, Cultured, 17-Hydroxysteroid Dehydrogenases, Androstane-3,17-diol, Gene Expression Regulation, Enzymologic, COS Cells, 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific), In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.